Annexon, Inc. (ANNX)
4.01
+0.60
(+17.60%)
USD |
NASDAQ |
Oct 19, 16:00
4.11
+0.10
(+2.49%)
After-Hours: 04:26
Annexon Enterprise Value : 515.57M for Oct. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 19, 2026 | 515.57M |
| October 16, 2026 | 410.81M |
| October 15, 2026 | 443.98M |
| October 14, 2026 | 456.21M |
| October 13, 2026 | 484.14M |
| October 12, 2026 | 506.84M |
| October 09, 2026 | 517.32M |
| October 08, 2026 | 513.82M |
| October 07, 2026 | 515.57M |
| October 06, 2026 | 519.06M |
| October 05, 2026 | 548.75M |
| October 02, 2026 | 547.00M |
| October 01, 2026 | 534.78M |
| September 30, 2026 | 553.98M |
| September 29, 2026 | 536.52M |
| September 28, 2026 | 515.57M |
| September 25, 2026 | 450.97M |
| September 24, 2026 | 478.90M |
| September 23, 2026 | 491.13M |
| September 22, 2026 | 545.25M |
| September 21, 2026 | 552.24M |
| September 18, 2026 | 553.98M |
| September 17, 2026 | 543.51M |
| September 16, 2026 | 501.60M |
| September 15, 2026 | 499.86M |
| Date | Value |
|---|---|
| September 14, 2026 | 505.09M |
| September 11, 2026 | 503.35M |
| September 10, 2026 | 538.27M |
| September 09, 2026 | 578.43M |
| September 08, 2026 | 630.81M |
| September 04, 2026 | 665.73M |
| September 03, 2026 | 660.49M |
| September 02, 2026 | 676.21M |
| September 01, 2026 | 669.22M |
| August 31, 2026 | 677.95M |
| August 28, 2026 | 683.19M |
| August 27, 2026 | 732.08M |
| August 26, 2026 | 686.68M |
| August 25, 2026 | 714.62M |
| August 24, 2026 | 698.91M |
| August 21, 2026 | 700.65M |
| August 20, 2026 | 719.86M |
| August 19, 2026 | 775.73M |
| August 18, 2026 | 737.32M |
| August 17, 2026 | 711.13M |
| August 14, 2026 | 739.06M |
| August 13, 2026 | 733.83M |
| August 12, 2026 | 746.05M |
| August 11, 2026 | 747.79M |
| August 10, 2026 | 756.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.526B |
| Alnylam Pharmaceuticals, Inc. | 30.88B |
| Anika Therapeutics, Inc. | 257.44M |
| Savara, Inc. | 808.37M |
| Vericel Corp. | 1.998B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.35M |
| Total Expenses (Quarterly) | 55.35M |
| EPS Diluted (Quarterly) | -0.2754 |
| Earnings Yield | -28.61% |
| Normalized Earnings Yield | -28.61 |